iCare HOME2 Clinical Trial

The aim of this clinical study is to provide information about the variability of the intraocular pressure (IOP) self-measurements with the iCare HOME2 tonometer in comparison to the variability of the IOP measurements with the reference tonometer (iCare IC200), over a wide range of IOP values.

Study Overview

• Status: Completed
• Conditions: Glaucoma; Intraocular Pressure
• Intervention / Treatment: Device: iCare HOME2 vs iCare IC200

Detailed Description

The clinical study is planned to estimate the variability of the IOP measurement of iCare HOME2 and IC200. In the study, the subjects will learn to operate the iCare HOME2 tonometer independently by using the labeling materials provided to them. Once they learn to operate the tonometer, subjects will take three self-measurements on the selected eye both in sitting and supine position.

The variability of the measurement results taken with iCare HOME2 will be compared to the variability of the measurement results taken with iCare IC200 by using the recorded results from the study subjects.

• Study Type: Interventional
• Enrollment (Actual): 47
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90013
      • East West Eye Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Glaucoma patients having confirmed optic nerve damage with visual field defects consistent with the glaucomatous optic neuropathy or
• Glaucoma-suspects being followed because of elevated IOP, and/or because of other risk factors for developing glaucoma or optic nerve damage.

Exclusion Criteria:

• Active ocular infection (e.g., pink eye or infectious conjunctivitis)
• Recent trauma to the eye including corneal laceration or corneal/scleral perforation
• Disabling arthritis or difficulty handling the tonometer
• Severe difficulty in opening the eyes including abnormal contractions or twitches of the eyelid (blepharospasm)
• Involuntary, rapid, and repetitive eye movements (nystagmus)
• Low uncorrected near visual acuity of 20/200 or below
• Significant glaucomatous central field loss
• Only one functional eye
• Poor or off-center visual fixation
• Poor hearing and/or communicates using sign language
• Keratoconus (or other corneal disorder)
• Congenitally small eye (microphthalmos)
• Enlarged eyeball from the childhood glaucoma (buphthalmos)
• Previous experience using or interacting with the HOME tonometer during usability tests or clinical trials
• Any affiliation with Icare and its employees
• High corneal astigmatism (>3d)
• History of prior invasive corneal surgery including corneal laser surgery less than six months ago (e.g., LASIK, LASEK, Smile)
• Corneal scarring
• Very thick or very thin corneas (central corneal thickness greater than 600 μm or less than 500 μm)
• Cataract extraction within the last 2 months
• Wearing contact lenses during the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: iCare HOME2 vs iCare IC200; Measurement of intraocular pressure (IOP) with iCare IC200 reference tonometer compared to iCare HOME2 test tonometer. Measurement will be performed to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (≥23 mmHg).	Device: iCare HOME2 vs iCare IC200; Measurement of IOP with iCare HOME2 compared with iCare IC200.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Repeatability of IOP measurements	Repeatability of IOP measurements comparison of iCare HOME2 vs iCare IC200	Through study completion, an average of 1-2 months

Collaborators and Investigators

• Sponsor: Icare Finland Oy
• Investigators: Principal Investigator: Michelle A Sato, MD, East West Eye Institute

Study record dates

Study Major Dates

• Study Start (Actual): November 26, 2021
• Primary Completion (Actual): December 15, 2021
• Study Completion (Actual): December 15, 2021

Study Registration Dates

• First Submitted: December 16, 2021
• First Submitted That Met QC Criteria: December 17, 2021
• First Posted (Actual): December 20, 2021

Study Record Updates

• Last Update Posted (Actual): December 20, 2021
• Last Update Submitted That Met QC Criteria: December 17, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Ocular Hypertension; Glaucoma
• Other Study ID Numbers: TA023-207

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes